Advertisement

Archives of Gynecology and Obstetrics

, Volume 298, Issue 4, pp 821–825 | Cite as

Galectin-3 as a novel biomarker in women with PCOS

  • Gokce Anik Ilhan
  • Cansu Kanlioglu
  • Gaye Arslan
  • Begum Yildizhan
  • Tanju Pekin
Gynecologic Endocrinology and Reproductive Medicine

Abstract

Purpose

This study aimed at evaluating galectin-3 levels as a novel metabolic biomarker in women with PCOS.

Methods

Ninety consecutive women with PCOS fulfilling the inclusion criteria were divided into two groups according to the presence of metabolic syndrome as MetS+ and MetS−. Clinical, hormonal, and metabolic parameters and galectin-3 levels were compared between the groups. Correlation analyses were performed between galectin-3 and clinical and metabolic parameters.

Results

Ninety PCOS subjects were enrolled in the study, 25 of which were diagnosed with MetS. Waist-to-hip ratio, systolic and diastolic blood pressures, triglyceride, HOMA-IR, FAI, FGS, and galectin-3 levels were significantly higher in the MetS+ group compared with the MetS− group (13.19 ± 5.63 vs 9.37 ± 3.99 ng/mL, respectively, p = 0.001). HDL cholesterol was significantly higher in the MetS− group than in the MetS+ one. Galectin-3 levels were found to be positively correlated with systolic blood pressure (r = 0.450, p < 0.01), diastolic blood pressure (r = 0.293, p < 0.01), and triglyceride levels (r = 0.218, p < 0.05) in women with PCOS.

Conclusions

Galectin-3 may be a promising novel biomarker in women with PCOS. Galectin-3 levels were significantly higher in the MetS+ group compared with the MetS− one and positively correlated with systolic, diastolic blood pressures and triglyceride levels in women with PCOS.

Keywords

Polycystic ovary syndrome Galectin-3 Metabolic syndrome Metabolic biomarker Cardiometabolic risk 

Notes

Acknowledgements

We declare that we have no conflict of interest.

Author contributions

GAI: Methodology, data collection, data analysis, writing and editing the manuscript; CK: Data collection; GA: Data collection; BY: editing the manuscript; TP: editing the manuscript.

Compliance with ethical standards

Ethical statement

The study protocol was approved by the Ethics Committee of the Marmara University.

Conflict of interest

The authors declare that they have no conflict of interest and funding was not received for performing the study.

References

  1. 1.
    Young DR, Hivert MF, Alhassan S et al (2016) Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. Circulation 134(13):e262–e279CrossRefPubMedGoogle Scholar
  2. 2.
    Grundy SM (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 92(2):399–404CrossRefPubMedGoogle Scholar
  3. 3.
    Dokras A, Bochner M, Hollinrake E et al (2005) Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106(1):131–137CrossRefPubMedGoogle Scholar
  4. 4.
    Pugliese G, Iacobini C, Pesce CM et al (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25(2):136–150CrossRefPubMedGoogle Scholar
  5. 5.
    Nayor M, Wang N, Larson MG et al (2015) Circulating galectin-3 is associated with cardiometabolic disease in the community. J Am Heart Assoc.  https://doi.org/10.1161/JAHA.115.002347 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lisowska A, Knapp M, Tycińska A et al (2016) Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: a mid-term prospective cohort study. Atherosclerosis 246:309–317CrossRefPubMedGoogle Scholar
  7. 7.
    Gehlken C, Suthahar N, Meijers WC et al (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14(1):75–92CrossRefPubMedGoogle Scholar
  8. 8.
    Miró Ò, González de la Presa B, Herrero-Puente P et al (2017) The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers 22(8):731–739CrossRefPubMedGoogle Scholar
  9. 9.
    Li P, Liu S, Lu M et al (2016) Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell 167(4):973–984CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yilmaz H, Cakmak M, Inan O et al (2015) Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor? J Endocrinol Investig 38(5):527–533CrossRefGoogle Scholar
  11. 11.
    Orio F, Palomba S Jr, Cascella T et al (2004) Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:4588–4593CrossRefPubMedGoogle Scholar
  12. 12.
    Orio F, Vuolo L, Palomba S et al (2008) Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 60(1):39–51PubMedGoogle Scholar
  13. 13.
    Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnosis criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19–25CrossRefGoogle Scholar
  14. 14.
    Hatch R, Rosenfield RL, Kim MH et al (1981) Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 140(7):815–830CrossRefPubMedGoogle Scholar
  15. 15.
    Matthews DR, Hosker JP, Rudenski AS et al (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome: a new worldwide definition. Lancet 366(9491):1059–1062CrossRefGoogle Scholar
  17. 17.
    Yilmaz H, Celik HT, Ozdemir O et al (2014) Serum galectin-3 levels in women with PCOS. J Endocrinol Investig 37(2):181–187CrossRefGoogle Scholar
  18. 18.
    Nayaker BS, Thomas S, Ramachandran S et al (2017) Polycystic ovarian syndrome-associated cardiovascular complications: an overview of the association between the biochemical markers and potential strategies for their prevention and elimination. Diabetes Metab Syndr.  https://doi.org/10.1016/j.dsx.2017.07.004 CrossRefPubMedGoogle Scholar
  19. 19.
    Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R et al (2017) The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clin Endocrinol (Oxf).  https://doi.org/10.1111/cen.13477 CrossRefGoogle Scholar
  20. 20.
    Cuspidi C, Sala C, Provenzano F et al (2018) Metabolic syndrome and subclinical carotid damage: a meta-analysis from population-based studies. J Hypertens 36(1):23–30CrossRefPubMedGoogle Scholar
  21. 21.
    Grandl G, Wolfrum C (2017) Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol.  https://doi.org/10.1007/s00281-017-0666-5 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861CrossRefPubMedGoogle Scholar
  23. 23.
    Dong R, Zhang M, Hu Q et al (2018) Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy. Int J Mol Med 41(2):599–614PubMedGoogle Scholar
  24. 24.
    Filipe MD, Meijers WC, Rogier van der Velde A et al (2015) Galectin-3 and heart failure: prognosis, prediction and clinical utility. Clin Chim Acta 443:48–56CrossRefPubMedGoogle Scholar
  25. 25.
    Agnello L, Bivona G, Lo Sasso B et al (2017) Galectin-3 in acute coronary syndrome. Clin Biochem 50(13–14):797–803CrossRefPubMedGoogle Scholar
  26. 26.
    Ozturk D, Celik O, Satilmis S et al (2015) Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis 26(5):396–401CrossRefPubMedGoogle Scholar
  27. 27.
    Caserta D, Adducchio G, Picchia S et al (2014) Metabolic syndrome and polycystic ovary syndrome: an intriguing overlapping. Gynecol Endocrinol 30(6):397–402CrossRefPubMedGoogle Scholar
  28. 28.
    Essah PA, Wickham EP, Nestler JE (2007) The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 50(1):205–225CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyMarmara UniversityIstanbulTurkey

Personalised recommendations